M
Manish Kumar Tripathi
Researcher at Indian Institutes of Technology
Publications - 36
Citations - 534
Manish Kumar Tripathi is an academic researcher from Indian Institutes of Technology. The author has contributed to research in topics: Acetylcholinesterase & Docking (molecular). The author has an hindex of 8, co-authored 32 publications receiving 261 citations. Previous affiliations of Manish Kumar Tripathi include Maulana Azad National Institute of Technology & All India Institute of Medical Sciences.
Papers
More filters
Journal ArticleDOI
Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor.
Manish Kumar Tripathi,Pushpendra Singh,Sujata Sharma,Tej P. Singh,Abdul S. Ethayathulla,Punit Kaur +5 more
TL;DR: The study suggests that Withanoside V in Ashwagandha may be serve as a potential inhibitor against Mpro of SARS-CoV-2 to combat COVID-19 and may have an antiviral effect on nCoV.
Journal ArticleDOI
Biphenyl-3-oxo-1,2,4-triazine linked piperazine derivatives as potential cholinesterase inhibitors with anti-oxidant property to improve the learning and memory.
Prabhash Nath Tripathi,Pavan Srivastava,Piyoosh Sharma,Manish Kumar Tripathi,Ankit Seth,Avanish Tripathi,Sachchida Nand Rai,Surya Pratap Singh,Sushant K. Shrivastava +8 more
TL;DR: The in vivo behavioral and ex vivo studies of compound 6g indicated significant improvement in cognitive dysfunctions against scopolamine-induced amnesia mouse models and a consensual binding affinity and active site interactions with the PAS and active catalytic site (CAS) residues of AChE.
Journal ArticleDOI
Design and Development of Multitarget-Directed N-Benzylpiperidine Analogs as Potential Candidates for the Treatment of Alzheimer's Disease
Piyoosh Sharma,Avanish Tripathi,Prabhash Nath Tripathi,Santosh Kumar Prajapati,Ankit Seth,Manish Kumar Tripathi,Pavan Srivastava,Vinod Tiwari,Sairam Krishnamurthy,Sushant K. Shrivastava +9 more
TL;DR: A series of N-benzylpiperidine analogs were designed and synthesized as multi-functional inhibitors of acetylcholinesterase (AChE) and β-secretase-1 (BACE-1) with moderate to excellent inhibitory activities, establishing the brain AChE inhibitory potential and antioxidant properties of these compounds.
Journal ArticleDOI
Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.
Avanish Tripathi,Priyanka Kumari Choubey,Piyoosh Sharma,Ankit Seth,Prabhash Nath Tripathi,Manish Kumar Tripathi,Santosh Kumar Prajapati,Sairam Krishnamurthy,Sushant K. Shrivastava +8 more
TL;DR: This work has designed and synthesized molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles that show significant and balanced inhibitory potential against target enzymes and ex vivo studies suggested decreased AChE activity and antioxidant potential of compound 49, with good oral absorption characteristics ascertained by pharmacokinetic studies.
Journal ArticleDOI
Design and development of novel p-aminobenzoic acid derivatives as potential cholinesterase inhibitors for the treatment of Alzheimer's disease.
Sushant K. Shrivastava,Saurabh K. Sinha,Pavan Srivastava,Prabhash Nath Tripathi,Piyoosh Sharma,Manish Kumar Tripathi,Avanish Tripathi,Priyanka Kumari Choubey,Digambar Kumar Waiker,Lalit Mohan Aggarwal,Manish Dixit,Subhash Chand Kheruka,Sanjay Gambhir,Sharmila Shankar,Rakesh K. Srivastava +14 more
TL;DR: In vivo studies of the synthesized compounds exhibited significant reversal of cognitive deficits in the animal models of amnesia as compared to standard drug donepezil, and the ex vivo studies in the specific brain regions like the hippocampus, hypothalamus, and prefrontal cortex regions also exhibited AChE inhibition comparable to standarddonepezil.